Photoclinic: Atypical Juvenile Dermatomyositis

Publication
Article
Consultant for PediatriciansConsultant for Pediatricians Vol 5 No 12
Volume 5
Issue 12

An 8-year-old boy whose family had recently immigrated from Southeast Asia was brought to the emergency department (ED) with a well-demarcated, pruritic rash that had appeared on his face 6 weeks earlier. At that time, the patient's primary care physician had diagnosed Fifth disease. As the rash spread to the child's arms and back, atopic dermatitis was considered. The week before presentation in the ED, the rash had become more inflamed and pruritic and was accompanied by fevers.

An 8-year-old boy whose family had recently immigrated from Southeast Asia was brought to the emergency department (ED) with a well-demarcated, pruritic rash that had appeared on his face 6 weeks earlier. At that time, the patient's primary care physician had diagnosed Fifth disease. As the rash spread to the child's arms and back, atopic dermatitis was considered. The week before presentation in the ED, the rash had become more inflamed and pruritic and was accompanied by fevers.

In the ED, the patient was in no acute distress. He was 50 kg (111 lb);temperature, 37.1°C (98.7°F); heart rate, 108 beats per minute; respiration rate, 22 breaths per minute; and blood pressure, 116/84 mm Hg. The rash was composed of confluent violaceous patches and minimally elevated plaques that blanched to pressure. Multiple excoriations were noted. There was no obvious eyelid edema or heliotropic rash.

Nathan Hitzeman, MD, and Mimi Reiss, MD, of Sacramento, Calif, considered a diagnosis of atypical eczema with superinfection. The patient was hospitalized and treated with oral antibiotics, corticosteroids, and antihistamines.

The consulting dermatologist elicited a history of at least 1 episode, about 2 weeks earlier, in which the patient had difficulty in standing up from a sitting position. Histologic analysis of a skin biopsy specimen showed increased mucin in the upper reticular dermis--a nonspecific characteristic of connective tissue disorders.

The differential diagnosis included atopic dermatitis, contact dermatitis, viral exanthem, juvenile rheumatoid arthritis, dermatomyositis, systemic lupus erythematosus, psoriasis, polymorphous light eruption, and drug reaction.

Several laboratory values were consistent with dermatomyositis: creatine kinase, 1362 U/L (normal range, 38 to 174 U/L); aldolase, 15.5 IU/L (normal range, 3.4 to 8.6 IU/L); and aspartate aminotransferase, 80 U/L.1 A muscle biopsy confirmed this diagnosis.

Juvenile dermatomyositis is uncommon. The peak incidence is between 5 and 14 years of age.2 The cause is unclear, but immunologic factors are suspected. Classic features of dermatomyositis (not seen in this patient) include:

•Gottron papules: violaceous papules found on the dorsal interphalangeal joints, metacarpophalangeal joints, knees, elbows, and medial malleoli.

•Gottron sign: symmetric erythematous or violaceous macules or plaques in the same distribution as the Gottron papules.

•Heliotropic rash: a reddish purple rash on the upper eyelids with periorbital swelling.

The "shawl" sign--which consists of poikilodermatous macules that appear in a "V" distribution over the shoulders, chest, and back--is a less common presentation of dermatomyositis and was seen in this patient.2,3

First-line treatment for dermatomyositis is a high-dose corticosteroid, such as prednisone (0.5 to 1.5 mg/kg).2,3 The dosage is slowly tapered after symptoms resolve and enzyme levels become normal. Methotrexate and cyclosporine are sometimes used in patients who do not respond to corticosteroid therapy.

The prognosis for patients with juvenile dermatomyositis is better than that for adults with dermatomyositis. The adult form is more commonly associated with an underlying malignancy. Calcinosis cutis, a benign skin condition that involves calcium deposition, may occur in up to 40% of patients with juvenile dermatomyositis. This condition is painful and disfiguring and is best prevented through early and aggressive treatment of dermatomyositis.3

This patient's rash became less pruritic and inflamed after several weeks of corticosteroid treatment.

References:

REFERENCES:


1.

Fischbach FT, Dunning MB III, eds.

A Manual of Laboratory and Diagnostic Tests.

7th ed. Philadelphia: Lippincott Williams and Wilkins; 2004:398, 1192.

2.

Koler RA, Montemarano A. Dermatomyositis.

Am Fam Physician.

2001;64:1565-1572.

3.

Callen JP. Dermatomyositis.

Lancet.

2000;355: 53-57.

Recent Videos
Wendy Ripple, MD
Wendy Ripple, MD
Lawrence Eichenfield, MD
Lawrence Eichenfield, MD | Image credit: KOL provided
FDA approves B-VEC to treat dystrophic epidermolysis bullosa patients 6 months and older | Image Credit: bankrx - Image Credit: bankrx - stock.adobe.com.
Related Content
© 2024 MJH Life Sciences

All rights reserved.